ArticleGenes2019
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Abstract read
In one paragraph
Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Medullary thyroid carcinoma with pheochromocytoma and cystic parathyroid degeneration in a ret-negative patient: a case report.Annals of medicine and surgery (2012) · 2026Article
- Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.Investigational new drugs · 2026Article
- Immunohistochemical expression of Ki-67, INSM1, and SSTR2A in medullary thyroid carcinoma: correlation with tumour size, vascular invasion, and biochemical outcome.Virchows Archiv : an international journal of pathology · 2026Article
- FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications.Endocrine-related cancer · 2026Review
- Atypical presentation and association of medullary thyroid carcinoma: reports from a tertiary care center in Northwest India.Endocrinology, diabetes & metabolism case reports · 2026Article
- Review
- Prevalence and genetics of "de novo" MEN2 syndromes.The Journal of clinical endocrinology and metabolism · 2025Article
- Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.JAMA network open · 2025Article
- Genomic testing for RET in the clinic: UK and global perspective.Endocrine-related cancer · 2025Review
- Review
- Mechanisms of resistance to RET-directed therapies.Endocrine-related cancer · 2025Review
- Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Molecular diagnostic approaches in detecting rearranged during transfection oncogene mutations in multiple endocrine neoplasia type 2.World journal of clinical cases · 2024Article
- The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.Deutsches Arzteblatt international · 2024Observational
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma.Journal of clinical medicine · 2024Review
- Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in Europe.European thyroid journal · 2024Article
- Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.Thyroid : official journal of the American Thyroid Association · 2024Article
- Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients.Frontiers in oncology · 2024Article
- Medullary Thyroid Cancer: Updates and Challenges.Endocrine reviews · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Rossella EliseiDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Alessia TacitoDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Teresa RamoneDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Raffaele CiampiDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Valeria BotticiDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Virginia CappagliDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
David ViolaDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Antonio MatroneDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Loredana LorussoDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Laura ValerioDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Carlotta GianiDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Cristina CampopianoDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Alessandro PreteDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Laura AgateDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Eleonora MolinaroDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy.
Cristina RomeiDepartment of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, 56124 Pisa, Italy. cristina.romei@unipi.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathogenic germline mutations affecting the
methodsWe performed
resultsA
conclusionsa)
Indexed as
Germ-Line MutationCarcinoma, MedullaryFemaleHumansMaleMultiple Endocrine Neoplasia Type 2aMutation RateProto-Oncogene MasProto-Oncogene Proteins c-retThyroid NeoplasmsMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-retRET protein, humangenetic screeningmedullary thyroid carcinomaRETVUS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.